KRASmut In Vivo Screen
Advance your KRAS-targeted therapeutic pipeline, featuring 40 precisely selected PDX mutant models, derived from 8 distinct tumor indications.
Targeting KRAS Mutations
Advance your KRAS inhibitors by assessing them on our industry-leading KRASmut In Vivo Screen. Gain access to a rich biobank of 40 pre-treated and naïve PDX models across 8 tumor indications, covering key cancer types like pancreatic, colorectal, and NSCLC with key KRAS mutations as G12C, G12D, G12R, G12V, and G13D. All our models are meticulously curated and retain clinically significant traits crucial for robust in vivo evaluation.
This screen offers an exceptional opportunity to evaluate the effectiveness of your KRAS inhibitors, with many models pre-treated with the latest generation of targeted therapies, closely resembling real-life patient responses. Contact us today to advance your cancer drug development project.
KRASmut In Vivo Screen offers:
- Comprehensive model characterization (stored in Lumin) with:
☑️Robust clinical data annotations
☑️NGS (RNAseq and WES) analysis
☑️Proteomics and phospho-proteomics - 50% off of a Standard of Care agent arm (selected by Champions)
- No minimum number of models to enroll and you have the ability to select the models you want to screen.
- Terminal tumor collections for target validation are available upon request (Snap Frozen/FFPE).
- Several endpoint data options available including Flow Cytometry and IHC to quantify target expression and critical phenotypical changes (available upon request).
![KRASmut Model Characteristcs Figure_May24](https://www.championsoncology.com/hs-fs/hubfs/KRASmut%20Model%20Characteristcs%20Figure_May24.png?width=2000&name=KRASmut%20Model%20Characteristcs%20Figure_May24.png)
Figure 1: Champions cutting-edge data interpretation software Lumin can generate extensive multi-omic data on 40 PDX models included in the KRASmut In Vivo Screen. These models span 8 tumor types and encompass various tumor statuses (primary vs metastatic), treatment histories (Naive vs pretreated), and mutation burdens. This wealth of information is invaluable to researchers, aiding them in their decision-making processes.
![KRASmut In Vivo Screen_Mutation Map_May24](https://www.championsoncology.com/hs-fs/hubfs/KRASmut%20In%20Vivo%20Screen_Mutation%20Map_May24.png?width=2000&name=KRASmut%20In%20Vivo%20Screen_Mutation%20Map_May24.png)
Figure 2: Our PDX models' KRAS mutation map illustrates the frequency and type of mutations within the gene. Each lollipop's height indicates mutation frequency, and dot color signifies mutation category (refer to Legend).